COORDINATION
Dr. Mafalda Oliveira, Hospital Vall d’Hebron/VHIO, Barcelona and President of SOLTI
Dr. Juan M. Ferrero-Cafiero, Chief Scientific Development Officer at SOLTI
AGENDA
10:00 | Welcome
Coordinators
10:10 | Improving outcomes in early HER2-negative breast cancer: new drugs, new combinations, new scenarios
Dr. David Cescon (Princess Margaret Cancer Centre, Toronto)
10:40 | Discussion
Coordinators
10:55 | Optimizing endocrine treatment in advanced ER+/HER2-negative breast cancer with new agents, combinations and strategies
Dr. François Clement Bidard (Institut Curie & UVSQ/Université Paris-Saclay, Paris)
11:25 | Discussion
Coordinators
11:40 | Break
12:10 | New generation of liquid biomarkers to detect minimal residual disease: sensitivity, limit of detection, and prediction of relapse. Where do we go from here?
Dr. Isaac Garcia-Murillas (Institute of Cancer Research, London)
12:40 | Discussion
Coordinators
12:55 | Multiomic approaches for biomarker discovery in metastatic breast cancer
Dr. Christine Desmedt (Katholieke Universiteit, Leuven)
13:25 | Discussion
Coordinators
13:40 | Conclusions
Coordinators
13:45 | Lunch + Satellite symposium